Major projects

• Lead in and out-licensing of several major branded products, e.g. Camptothecin, G-CSF and Docetexol
• M&A and JV transactions of 11 major pharmaceutical companies in Japan, USA and EU
• Acquisition of 11 major branded products
• Establishment of a JV between Actavis Group and Aska Pharma, a Takeda Group company
• Establishment of Actavis' oncology business in Japan

Experience

• Since 2010 Executive Representative, Takanawa Pharma
• 2007 – 2011 Senior Advisor, Actavis Group
• 2004 – 2011 Senior Advisor, Sanofi Pasteur
• 2000 – 2004 Board Member, Head of Global Business Development, Sanofi Japan (Then Aventis Pharma)
• 1996 – 2000 Board Member, Business Development, Sanofi Japan (Then Rhone-Poulenc Rorer)
• 1991 – 1995 Executive Director, Business Development (Asia-Pacific), Sanofi Japan (Then Rhone-Poulenc Rorer)
• 1985 – 1991 General Manager, Business Development (Asia-Japan), Sanofi Japan (Then Rhone-Poulenc Sante)
• 1981 – 1985 Director, R&D Planning and Licensing, Kaken Pharmaceutical
• 1974 – 1976 Manager, Pharmacology and Biochemistry Division, Kaken Pharmaceutical

Education

• Ph.D. in Pharma Science, Kyoto University
• B.Sc. in Pharma Science, Kyoto University
• Scientist at National Institute of Radiological Medicines, Chiba
• Visiting scientist at NIH, Bethesda, USA

Civic Engagement

• 2013 – 2019 Director at the Icelandic Chamber of Commerce in Japan
• 1998 – 2002  Director, Japan Pharma Licensing Association